Evidence map›Paper›PMID 42719490›Full record

ArticleCureus2026

Late-Diagnosed Cystic Fibrosis in an Octogenarian With an Atypical Phenotype of Pancreatic Sufficiency and Preserved Pulmonary Function.

Brenda Hranec, Luke Hudson, Daniel Layish

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Brenda HranecCollege of Medicine, Florida State University, Tallahassee, USA.
Luke HudsonCollege of Medicine, Florida State University, Tallahassee, USA.
Daniel LayishPulmonary Medicine, AdventHealth Orlando, Orlando, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cystic fibrosis (CF) was historically described as a severe childhood disease associated with pancreatic destruction, malnutrition, recurrent respiratory infection, and early mortality. Advances in sweat chloride testing, cystic fibrosis transmembrane conductance regulator (CFTR) gene discovery, newborn screening, multidisciplinary care, and CFTR modulator therapy have transformed the natural history of the disease. However, CF remains clinically heterogeneous, and patients with residual CFTR function may present later in life with chronic bronchiectasis, sinus disease, atypical respiratory infections, or nonspecific gastrointestinal symptoms. Diagnosis in advanced age is uncommon and may be delayed when pancreatic function is preserved and sweat chloride values are intermediate. An 87-year-old woman with late-diagnosed cystic fibrosis was followed longitudinally for chronic sinopulmonary disease. She had a history of recurrent sinus infections and was evaluated at a tertiary institution, where CF was diagnosed at approximately age 62. Her family history was notable for a maternal aunt who died from an unspecified respiratory illness. Diagnostic evaluation demonstrated an intermediate sweat chloride value of 41 mmol/L and CFTR testing showing one copy of F508del, M470V polymorphism, and a rare C76W variant. Her phenotype included chronic bronchiectasis, chronic sinusitis with nasal polyps, two prior sinus surgeries, and prior

Indexed as

bronchiectasiscftr modulatorchronic sinusitiscystic fibrosiselderlylate diagnosisoctogenarianpancreatic sufficiencypseudomonas aeruginosa

Identifiers

PMID42719490
PMCPMC13557706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.